Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blinded antipsychotic withdrawal trial in adults with intellectual disability and challenging behavior
NL-OMON55806Phase 3Completed
- Sponsor
- Erasmus MC
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, double-blind trial of risperidone and pipamperone in intellectual disability (ID) (2 arms), sponsored by Erasmus MC. Primary endpoint: Primary outcome: failure rate / dropout rate. Started Mar 2019; status: completed.
02
Drugs
risperidonepipamperone
03
Conditions
intellectual disability (ID)
Beyond the preview
Go deeper on NL-OMON55806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55806.